Mitochondrial transfer is known to occur from the tumor microenvironment into cancer cells, but now, Swiss researchers have shown a possible precursor to this is that cancer cells smuggle their mitochondria into healthy connective tissue cells, prompting their reprogramming to cancer-associated fibroblasts. Read More

Researchers at Seoul National University and the National Cancer Center examined public datasets from patients as well as the whole-exome sequence from one of their own patients, who developed radiation-induced sarcoma after treatment. Read More

Medipal Holdings Corp. and JCR Pharmaceuticals Co. Ltd. have signed an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479, an investigational therapy for the lysosomal storage disorder GM2 gangliosidosis. Read More

Effective vaccines against Staphylococcus aureus remain out of reach: 10 candidates that showed promise in preclinical animal models have failed in clinical trials. Researchers at Third Military Medical University and collaborators reasoned that one of the reasons might be that 70%-80% of the population has developed antibodies to the pathogen. Read More

Intelligen Therapeutics Co. Ltd. and Intelligen Therapeutics Inc. have disclosed macrocyclic compounds acting as TNF-α inhibitors reported to be useful for the treatment of inflammation and autoimmune diseases. Read More

Researchers at Zhengzhou University and two of its affiliated hospitals explored in a mouse model whether brozopine might mitigate ischemia-induced vascular dementia. Read More

Samjin Pharmaceutical Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, inflammatory bowel disease, arthritis and migraine. Read More

Shanghai Helioson Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases. Read More

The WEE1 tyrosine kinase is an important cell cycle regulator that inhibits cell cycle progression during the S and G2/M phases to impede the division of cells with DNA damage. Tumor cells with replicative stress are thought to rely on WEE1 for their survival. Read More

Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have divulged glucagon-like peptide 2 receptor (GLP-2R) agonists reported to be useful for the treatment of Crohn’s disease, irritable bowel syndrome, malnutrition, ulcerative colitis, obesity and graft-vs.-host disease. Read More

Scientists at Emory University and Hadasit Medical Research Services and Development Ltd. have described nuclear receptor ROR-α agonists reported to be useful for the treatment of liver cancer, pancreatitis, diabetes, obesity, immunological disorders, neurological disorders, liver diseases and metabolic diseases, among others. Read More

The TCF4/β-catenin axis is a key driver of tumor growth, where β-catenin has remained resistant to therapy and is traditionally considered an undruggable protein. At the ACS Fall 2025 meeting, Parabilis Medicines Inc. divulged results of work on hyperstabilized α-helical peptides named helicons that directly bind to β-catenin and block its interaction with TCF transcription factors such as TCF4, as well as inhibit the Wnt signaling pathway. Read More